Palantir's 6-Day Plunge: Is the Selloff Over or Just Beginning?

Palantir Technologies ( $Palantir Technologies Inc.(PLTR)$ ) is enduring a brutal downturn, with shares tumbling for the sixth consecutive session on August 20, 2025, closing down 1.10% at $156.01—a 18% retreat from its record high of $190.50 on August 12. This extended slump, the longest since April 2024, has erased $73 billion in market value despite a stellar Q2 earnings report that pushed revenue past $1 billion for the first time. With the S&P 500 at 6,466.58, Bitcoin at $115,000, and oil at $75/barrel amid 30-35% tariffs, the tech sector's volatility is amplified. The VIX at 14.49 suggests calm, but Palantir's RSI at 42 signals potential oversold conditions. Is this healthy profit-taking after a 93% year-to-date gain, or the onset of a bigger correction? Should you buy the dip at $150, or is $40 a fair price as Citron Research claims? This in-depth analysis explores the drivers, market sentiment, and strategies to navigate Palantir's pivotal moment.

The Freefall Breakdown: What Triggered the Plunge?

Palantir's decline stems from a confluence of factors:

Profit-Taking Pressure: After a 93% year-to-date rally to $156.01, investors cashed in, with the stock dropping 18% in six days, erasing $73 billion in value amid broader tech reassessment.
Valuation Concerns: Trading at a forward P/E of 268x, far above the S&P 500's 21x, Palantir faces scrutiny from shorts like Citron Research, which targeted $40-$50, implying a 70-74% downside from $156.01.
Earnings Afterglow Fades: Q2 revenue of $678 million (up 27% YoY) and a $1 billion milestone initially sparked gains, but slowing U.S. commercial growth (20% vs. 54% in 2024) and a 95% MIT report on zero AI ROI fueled doubts.
Market Rotation: Tech's weekly 2.4% dip, while healthcare rose 4%, suggests a shift from high-growth names like Palantir, with its $148 billion market cap now under pressure.
Technical Warning: The 50-day moving average at $145 and support at $150 are being tested, with resistance at $165; a break below $150 could accelerate losses to $125, per TradingView data.

Posts found on X reflect a divide, with bulls defending Palantir's AI contracts and bears echoing Citron's "overvalued" call, suggesting sentiment is at a tipping point.

Market Context: Correction or Consolidation?

The broader landscape adds nuance:

Tech Volatility: The Nasdaq's 21,713.14 peak contrasts with Palantir's slump, as peers like NVIDIA ($141.20, up 28% YTD) and AMD ($174.50, up 22% YTD) hold firm, but a 5-10% sector dip could drag Palantir to $140 if AI skepticism deepens.
Macro Risks: Tariffs and a potential Fed rate cut delay (83% probability for September) could pressure growth stocks, with Prism Capital's 0.9% GDP cut forecast adding to the mix.
Global Cues: U.S. retail sales up 0.3% in July and India's 100 GW solar milestone support tech, but KCB Group's 8% profit rise in Kenya hints at emerging market resilience that Palantir's international revenue (34%) could leverage.
Sentiment Shift: Analyst consensus holds a $134.72 12-month target, down 13% from $156.01, with 21 neutral ratings out of 27, per Nasdaq data, reflecting caution.
Volatility Check: The VIX at 14.49 suggests stability, but a spike to 17-20 could test Palantir's $150 support, with 12.3 million shares traded yesterday above average.

The pullback could be a pause, but macro and valuation risks loom large.

Profit-Taking or Bigger Correction? The Week’s Outlook

Is this a temporary breather or a deeper dive?

Bull Case: A rebound to $165 (5% upside) is possible by Friday, August 22, if $150 holds and AI contracts like the $1.2 billion backlog shine, with a 12-month target of $200 (28% gain) if growth accelerates.
Bear Case: A 5-10% drop to $142-$148 looms if $150 breaks, with $125 as a floor; Citron's $40 target implies a 74% downside if AI demand falters.
Growth Momentum: Q2's $1.04 billion revenue (up 48% YoY) and raised guidance to $4.14-$4.15 billion for 2025 suggest resilience, but H1's 20% U.S. commercial growth slowdown raises doubts.
Catalyst Watch: Jackson Hole Symposium (August 21-23) Fed comments and Q3 guidance previews could sway sentiment, with tariff escalations or profit-taking testing the rally.
Daily Forecast: $152-$160 (Wednesday), $150-$158 (Thursday), $148-$165 (Friday), per analyst trends, with $150 as the pivotal level.
Long-Term View: If revenue hits $5 billion by 2026 and margins rise to 30%, a $250 target (60% upside) is feasible, but a macro downturn could cap gains at $100 (36% downside).

The outlook leans toward consolidation, but risks are real.

Is Palantir Still Your Favorite? Sleeper or Slump?

Palantir's 100%+ year-to-date gain to $158 makes it a favorite for many, but the pullback has sparked debate:

Bull Argument: Its $2.5 billion annual contract value and 104 deals over $1 million highlight long-term strength, with a rebound to $165-$170 possible this week if $150 holds.
Bear Argument: Citron's $40-$50 target and a 95% MIT report on zero AI ROI question its 268x forward P/E, suggesting a bigger correction to $125 if sentiment sours.
Favorite Status: Posts found on X show bulls defending its AI edge, while bears call it an "overvalued trap," reflecting a split sentiment.
Valuation Check: At $40, a 74% drop, it trades at a 20x P/E on $5 billion projected revenue, aligning with traditional software peers like Microsoft (30x).
Long-Term Play: If AI contracts grow to $1.5 billion quarterly by 2026, a $200 target (27% upside) is in sight, but execution risks echo in the current slump.

Palantir remains a favorite for AI believers, but the dip tests loyalty.

Trading Strategies: Navigate the Pullback

Short-Term Plays

Buy the Dip: Buy at $150-$152, target $165-$170, stop at $147. A 9-12% gain if support holds.
Bearish Hedge: Buy puts at $150, target $140, stop at $153. A 6-7% win if correction deepens.
Sector Pivot: Buy Health Care ETF (XLV) at $150, target $155, stop at $148. A 3% gain if rotation continues.
Profit Lock: Sell at $160-$162, target $155-$158, stop at $165. A 2-3% gain if volatility spikes.
Options Play: Buy $165 calls or $140 puts (August expiry) for 150-200% gains on a 5-10% move.

Long-Term Investments

Hold Palantir: Buy at $150-$152, target $200-$250 by 2026, for 27-58% upside if AI growth holds. Stop at $140.
Diversify Up: Buy CVS Health at $65-$67, target $77-$80, for 15-23% upside. Stop at $62.
Value Bet: Buy Pfizer ( $Pfizer(PFE)$ ) at $27-$28, target $35-$38, for 26-36% upside. Stop at $25.
Defensive Hold: Buy PepsiCo ( $Pepsi(PEP)$ ) at $185-$187, target $200-$210, for 7-13% upside. Stop at $180.

Hedge Strategies

VIXY ETF: Buy at $14, target $17, stop at $12, to hedge volatility.
SPY Puts: Use puts at 6,400 for a 5-10% market drop.
Gold ( $SPDR Gold Shares(GLD)$ ): Buy at $200, target $210, stop at $195, as a buffer.

My Trading Plan: Betting on a Rebound

I’m diving into Palantir’s dip with a strategic approach. I’ll buy at $150-$152, targeting $165, with a $147 stop, betting on a rebound if support holds. I’ll add CVS Health at $65-$67, aiming for $75, with a $62 stop, for diversification. I’ll include Pfizer at $27-$28, targeting $32, with a $25 stop, and PepsiCo at $185-$187, targeting $195, with a $180 stop. I’m hedging with VIXY at $14, targeting $16, and holding 20% cash for a drop to $140 or tariff news. I’ll monitor AI contract updates and Fed signals closely.

Key Metrics

The Bigger Picture

Palantir’s 9% plunge to $158 on August 19, 2025, marks its sixth day of losses, dropping 15% from $187, against a 6,466.58 S&P 500 and $115,000 Bitcoin. A 4-6% rebound to $165 is possible this week if $150 holds, with a $200 target (27% upside) by 2026 if AI growth persists. A 5-10% dip to $142-$148 looms if $150 breaks, potentially signaling a 20% correction to $126 if macro risks like tariffs (30-35%) or AI skepticism intensify. The 112% YTD gain and $1 billion revenue milestone show strength, but Citron’s $40 target and high P/E (245x) fuel doubt. Buy the dip with VIXY or GLD hedges, and monitor Fed signals. This could be your chance to win big.

Is Palantir’s dip your buy signal or a red flag? Share your view below! 🎁

📢 Like, repost, and follow for daily updates on market trends and stock insights.

📝 Disclaimer: This post is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.

📌@Daily_Discussion @Tiger_comments @TigerStars @TigerEvents @TigerWire @CaptainTiger @MillionaireTiger

Palantir Secures £1.5B UK Deal: Up 134% YTD! Still Room to Run?

UK will significantly increase purchases of Palantir Technologies (PLTR) data analytics software, with the U.K. military committing over $1 billion over five years, extending an earlier deal, according to Bloomberg. Following the news, Palantir shares rose 5.1% to close at $176.97. Year-to-date, the stock is up about 134% in 2025, though it remains below its all-time high of $190 on August 12. 👉 With continued government adoption and long-term contracts, could Palantir sustain its strong 2025 rally, or is a consolidation phase likely?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.